Barchart.com
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Get your Portfolio automatically emailed to you up to 4 times a day with Barchart Premier. FREE 30 Day Trial
Menu
Stocks | Futures | Watchlist | More
 
or
Watchlist | Portfolio
Site News
Contact
Market:

Orexo Ab (ORXOY)

Orexo Ab (ORXOY)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Notes
Alerts
Watch
Help
Go To:
Orexo announces data from the MODIA® study evaluating impact on use of illicit opioids PR Newswire - Wed Oct 11, 2023

The six-month randomized controlled trial (RCT) enrolled 437 participants at 36 sites across the US The study demonstrated no statistically significant...

ORXOY : 1.4000 (-2.78%)
Orexo submits New Drug Application to FDA for OX124, a high-dose rescue medication for opioid overdose PR Newswire - Mon Sep 18, 2023

/PRNewswire/ -- Orexo AB (publ.), (STO: ORX) (OTCQX: ORXOY), today announces the submission of the New Drug Application (NDA) to the US Food and Drug...

ORXOY : 1.4000 (-2.78%)
Orexo to participate in Pareto Securities´ 14th Annual Healthcare Conference 2023 PR Newswire - Tue Sep 5, 2023

/PRNewswire/ -- Orexo AB (Publ.), (STO:ORX) (OTCQX:ORXOY), today announces the company will participate in Pareto Securities' 14th Annual Healthcare...

ORXOY : 1.4000 (-2.78%)
Orexo secures patent protection in the US for OX640, a nasal epinephrine powder product PR Newswire - Tue Aug 29, 2023

/PRNewswire/ -- Orexo AB (publ.), (STO: ORX) (OTCQX: ORXOY) today announces that the United States Patent and Trademark Office (USPTO) has granted the first US...

ORXOY : 1.4000 (-2.78%)
Orexo's patent win for ZUBSOLV® appealed PR Newswire - Mon Jul 24, 2023

/PRNewswire/ -- Orexo AB (publ.), (STO: ORX) (OTCQX: ORXOY), today announces that Sun Pharmaceutical Industries Limited, Sun Pharma Global FZE, Sun Pharma...

ORXOY : 1.4000 (-2.78%)
Orexo wins patent litigation for ZUBSOLV® in the US PR Newswire - Sat Jul 1, 2023

/PRNewswire/ -- Orexo AB (publ.), (STO: ORX) (OTCQX: ORXOY), today announces that the US District Court for the District of New Jersey ruled in favor of Orexo...

ORXOY : 1.4000 (-2.78%)
Orexo shares new timeline for the high-dose rescue medication for opioid overdose, OX124 PR Newswire - Mon Apr 3, 2023

/PRNewswire/ -- Orexo AB (publ.), (STO:ORX) (OTCQX:ORXOY), today announces the expected US launch of OX124, a high-dose rescue medication for opioid overdose,...

ORXOY : 1.4000 (-2.78%)
Orexo postpones publication of the Annual Report PR Newswire - Wed Mar 15, 2023

/PRNewswire/ -- Orexo AB (publ), (STO:ORX) (OTCQX:ORXOY), has resolved to postpone the publication of the Annual Report for 2022 to March 28, 2023. The...

ORXOY : 1.4000 (-2.78%)
Orexo submits New Drug Application to FDA for OX124, a high-dose rescue medication for opioid overdose PR Newswire - Fri Feb 3, 2023

/PRNewswire/ -- Orexo AB (publ.), (STO: ORX) (OTCQX: ORXOY), today announces the submission of a New Drug Application (NDA) to the US Food and Drug...

ORXOY : 1.4000 (-2.78%)
Orexo initiates exploratory feasibility studies of amorphOX® with two leading biopharmaceutical and vaccine companies PR Newswire - Mon Jan 9, 2023

/PRNewswire/ -- Orexo AB (publ.), (STO:ORX) (OTCQX:ORXOY), today announces the company has initiated two exploratory feasibility studies, applying the...

ORXOY : 1.4000 (-2.78%)

Barchart Exclusives

Stocks Plunge Before the Open as Meta’s Revenue Forecast Disappoints, U.S. GDP Data and Earnings in Focus Barchart - 35 minutes ago
June S&P 500 E-Mini futures (ESM24) are down -0.53%, and June Nasdaq 100 E-Mini futures (NQM24) are down -0.87% this morning as a disappointing revenue outlook for the current quarter from Meta weighed on sentiment, while market participants braced for a new round of U.S. economic data and quarterly reports from heavyweight names. Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar

[[ data.userDate ]]
[[ data.eventTime | date: 'EEE, MMM dd, yyyy h:mm a' ]] [[ zone ]]
Reserve Your Spot